OPKO Health (OPKO Health) ROCE % : -15.06% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is OPKO Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OPKO Health's annualized ROCE % for the quarter that ended in Dec. 2023 was -15.06%.

OPKO Health ROCE % Historical Data

The historical data trend for OPKO Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health ROCE % Chart

OPKO Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-13.42

3.40

0.23

-18.86

-9.07

OPKO Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-20.22	-2.79	-2.72	-15.84	-15.06

OPKO Health ROCE % Calculation

OPKO Health's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-170.813	/	( ( (2167.259 - 213.48)	+	(2011.698 - 200.052) )	/ 2 )
	=	-170.813	/	( (1953.779	+	1811.646)	/ 2 )
	=	-170.813	/	1882.7125
	=	-9.07 %

OPKO Health's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-276.164	/	( ( (2056.68 - 200.554)	+	(2011.698 - 200.052) )	/ 2 )
	=	-276.164	/	( ( 1856.126	+	1811.646 )	/ 2 )
	=	-276.164	/	1833.886
	=	-15.06 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

OPKO Health (NAS:OPK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OPKO Health ROCE % Related Terms

Thank you for viewing the detailed overview of OPKO Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OPKO Health (OPKO Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OPK:Mexico OPK:Israel XCY:Germany XCY:Germany

Address

4400 Biscayne Boulevard, Miami, FL, USA, 33137

Website

https://www.opko.com

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel	director, officer: Chief Innovation Officer	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni	director, officer: Vice Chairman and President	2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli	director, other: Chairman of the Board	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen	director, officer: SVP OPKO; Exec Chairman BRLI	C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel	director	1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez	officer: CAO, Treasurer	C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel	director	C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal	officer: Exec.Dir .of Fin., CAO,Treas.	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137